Obesity
From an endocrine perspective, obesity involves genuine hormonal dysregulation -- disrupted leptin, ghrelin, and insulin signaling -- not simply excess calories, and is now treated as a chronic disease requiring long-term management per a 2026 synthesis of contemporary obesity guidelines.
Symptoms
Obesity is defined by BMI rather than symptoms, but the hormonal disruption it causes and responds to is measurable: insulin resistance, disrupted appetite signaling, low testosterone in men, and menstrual irregularity in women.
Causes and risk
Genetics, medications, sleep, stress, and food environment all interact with appetite-regulating hormones; a full endocrine workup screens for thyroid dysfunction, Cushing's syndrome, and PCOS as contributing or complicating factors, though these are far less common than primary obesity itself.
How it is evaluated
Beyond BMI and waist circumference, endocrine evaluation includes metabolic labs and screens for the hormonal conditions above when the clinical picture suggests them.
Treatment
GLP-1 and GIP/GLP-1 receptor agonists work specifically by restoring signaling along the same gut-brain hormonal axis that is disrupted in obesity, per the 2022 AGA guideline (appropriate at BMI 30+, or 27+ with a comorbidity). Bariatric surgery criteria are BMI 35+, or 30+ with a metabolic condition.
When to seek care
Obesity itself is not an emergency, but its complications can be: chest pain, stroke symptoms, acute pancreatitis, or severe sleep apnea with breathing pauses warrant urgent evaluation.